Reirradiation plus EGFR inhibition in locally recurrent and unresectable head and neck cancer: Final results from a single institution

Strahlentherapie und Onkologie

Volumn 189, Issue 10, 2013, Pages 842-848

  Milanovic D ^a   Jeremic B ^b   Grosu, A L ^a   Rucker G ^a   Henke, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Cetuximab; Chemotherapy; Epidermal growth factor receptor; Head and neck neoplasms; Reirradiation

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACNE; ADJUVANT CHEMORADIOTHERAPY; ADULT; AGED; ANAPHYLACTIC SHOCK; ARTICLE; BLOOD TOXICITY; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DERMATITIS; DRUG ERUPTION; DYSPHAGIA; FEASIBILITY STUDY; FEMALE; FIBROSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERPIGMENTATION; HYPOPHARYNX CARCINOMA; INOPERABLE CANCER; LARYNX CARCINOMA; LOADING DRUG DOSE; MALE; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECEPTOR BLOCKING; RECURRENT CANCER; RETREATMENT; RETROSPECTIVE STUDY; SECOND CANCER; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRISMUS; VOICE CHANGE; XEROSTOMIA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84887300687     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-013-0402-6     Document Type: Article

References (36)

1. Adelstein DJ, Li Y, Adams GL et al (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92-98
2. Balermpas P, Keller C, Hambek M et al (2012) Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. Int J Radiat Oncol Biol Phys 83:377-383
3. Baselga J (2001) The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37(Suppl 4):S16-S22
4. Bernier J, Domenge C, Ozsahin M et al (2004) European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945-1952
5. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578
6. Bonner JA, Raisch KP, Trummell HQ et al (2000) Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18:47S-53S
7. Coatesworth AP, Tsikoudas A, MacLennan K (2002) The cause of death in patients with head and neck squamous cell carcinoma. J Laryngol Otol 116:269-271
8. Comet B, Kramar A, Faivre-Pierret M et al (2012) Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 84:203-209
9. Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198-1205
10. De Crevoisier R, Bourhis J, Domenge C et al (1998) Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16:3556-3562
11. Dittmann K, Mayer C, Fehrenbacher B et al (2005) Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182-31189
12. Forastiere AA, Leong T, Rowinsky E et al (2001) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088-1095
13. Gibson MK, Li Y, Murphy B et al (2005) Eastern Cooperative Oncology Group. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562-3567
14. Haddad RI, Shin DM (2008) Recent advances in head and neck cancer. N Engl J Med 359:1143-1154
15. Harari PM, Huang SM (2001) Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 11:281-289
16. Hoebers F, Heemsbergen W, Moor S et al (2011) Reirradiation for head-and-neck cancer: delicate balance between effectiveness and toxicity. Int J Radiat Oncol Biol Phys 81:e111-e118
17. Jeremic B, Shibamoto Y, Milicic B et al (2000) Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18:1458-1464
18. Jeremic B, Shibamato Y, Stanisavljevic B et al (1997) Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 43:29-37
19. Langer CJ, Harris J, Horwitz EM et al (2007) Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol 25:4800-4805
20. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11:9-22
21. Licitra L, Störkel S, Kerr KM et al (2013) Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 49:1161-1168
22. Milanovic D, Jeremic B, Kayser G et al (2012) Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade. Strahlenther Onkol 188:518-522
23. Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumorresponse to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966-971
24. Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol
25. Pignon JP, le Maitre A, Maillard E, Bourhis J (2009) MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4-14
26. R Development Core Team (2009) A language and environment for statistical computing. R Foundation for Statistical Computing. http://www.R-project.org ISBN 3-900051-07-0
27. Salomon DS, Brandt R, Ciardiello F, Normanno N (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
28. Spencer SA, Harris J, Wheeler RH et al (2008) Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 30:281-288
29. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176-181
30. Tsuchihashi Z, Khambata-Ford S, Hanna N, Jänne PA (2005) Responsiveness to cetuximab without mutations in EGFR. N Engl J Med 353:208-209
31. Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127
32. Vormittag L, Lemaire C, Radonjic D et al (2012) Re-irradiation combined with capecitabine in locally recurrent squamous cell carcinoma of the head and neck. A prospective phase II trial. Strahlenther Onkol 188:235-242
33. Wong LY, Wei WI, Lam LK, Yuen AP (2003) Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 25:953-959
34. Wong SJ, Machtay M, Li Y (2006) Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 24:2653-2658
35. Wong SJ, Bourhis J, Langer CJ (2012) Retreatment of recurrent head and neck cancer in a previously irradiated field. Semin Radiat Oncol 22:214-219
36. Zwicker F, Roeder F, Thieke C et al (2011) IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol 187:32-38